AB
ADMA
HealthcareADMA Biologics, Inc.
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
8
LegalBearishPR NewswireMar 31, 2026
ADMA Biologics Investigated for Securities Fraud Following Culper Research Channel Stuffing Allegations
- ▸BFA Law investigating potential federal securities law violations
- ▸Culper Research alleges 2025 revenue growth was masked by channel stuffing
- ▸Report claims 2025 real growth was -3% versus 20% reported
- ▸Allegations include use of undisclosed related party distributor and excess inventory incentives
- ▸Stock price fell 29% over two trading days following report release
8
LegalBearishPR NewswireMar 30, 2026
ADMA Biologics shares slide 16% following Culper Research channel stuffing allegations
- ▸Shares fell 16% on March 24, 2026, following Culper Research report
- ▸Days Sales Outstanding (DSO) spiked to 113 days from 43 days YoY
- ▸Short report alleges channel stuffing via rebates and extended payment terms
- ▸Allegations claim 2025 revenue growth was fabricated; real growth estimated at -3%
- ▸Hagens Berman law firm launched investigation into potential securities law violations
7
BuybackBullishPer-CompanyMar 23, 2026
ADMA Biologics initiates $200M capital return program including $125M accelerated share repurchase
- ▸Initiated $200M total capital return program for 2026
- ▸Executed $125M accelerated share repurchase (ASR) agreement with JPMorgan
- ▸Initial delivery of 6.4 million shares expected on or about March 3
- ▸ASR represents 80% of anticipated total repurchases under current agreement
- ▸Part of broader $500M repurchase authorization approved in May 2025